The last collaboration of the famous Insilico Medicine Hong Kong company is the Pfizer laboratories. After a very busy year 2019 with publications in Nature Biotechnology and more than 35 millions dollars rond, the company increase partnership in the pharmaceutical domain. His patented technology is focused on the use of AI algorithms to find best combinations between drugs and molecular targets. This way to find new drugs could be the game changer in the future 10 years, especially to retarget known drugs.
“We look forward to working with Insilico as Pfizer continues to explore new technologies that may be able to help us identify targets and biomarkers that could assist in our discovery programs, and potentially lead to breakthrough therapeutics for patients with unmet medical needs,” said Morten Sogaard, Vice President, Target Sciences, Pfizer.